Sarah M. Romano's most recent trade in Entero Therapeutics Inc. was a trade of 727 Common Stock done at an average price of $0.6 . Disclosure was reported to the exchange on Jan. 6, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Entero Therapeutics Inc. | Sarah M. Romano | Chief Financial Officer | 06 Jan 2025 | 727 | 17,287 (0%) | 0% | 0.6 | 465 | Common Stock | |
Entero Therapeutics Inc. | Sarah M. Romano | Chief Financial Officer | 09 Oct 2024 | 476 | 18,014 (0%) | 0% | 0.4 | 212 | Common Stock | |
Entero Therapeutics Inc. | Sarah M. Romano | Chief Financial Officer | 02 Jul 2024 | 621 | 18,490 (0%) | 0% | 1.1 | 664 | Common Stock | |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.23 per share. | 01 Apr 2024 | 75 | 19,111 (0%) | 0% | 4.2 | 317 | Common Stock |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.96 per share. | 15 Mar 2024 | 1,120 | 19,186 (0%) | 0% | 5.0 | 5,555 | Common Stock |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.20 per share. | 12 Jan 2024 | 98 | 20,306 (0%) | 0% | 4.2 | 412 | Common Stock |
First Wave BioPharma Inc | Sarah Romano M. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 12,614 | 13,404 (0%) | 0% | 0 | Common Stock | |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 7,000 | 20,404 (0%) | 0% | 0 | Common Stock | |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.54 per share. | 03 Jul 2023 | 1,977 | 17,476 (0%) | 0% | 1.5 | 3,045 | Common Stock |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 03 Apr 2023 | 1,975 | 19,453 (0%) | 0% | 2.5 | 4,938 | Common Stock |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 150,000 | 150,000 | - | - | Stock option (right to buy) | |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.08 per share. | 05 Jan 2022 | 114 | 22,854 (0%) | 0% | 1.1 | 123 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 07 Dec 2021 | 91 | 22,968 (0%) | 0% | 1.3 | 118 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 02 Nov 2021 | 83 | 23,059 (0%) | 0% | 2.0 | 164 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.01 per share. | 04 Oct 2021 | 83 | 23,142 (0%) | 0% | 2.0 | 167 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 02 Sep 2021 | 84 | 23,225 (0%) | 0% | 1.8 | 152 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 87 | 23,309 (0%) | 0% | 2.4 | 209 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 180 | 23,396 (0%) | 0% | 3.7 | 666 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 180 | 23,576 (0%) | 0% | 4.2 | 754 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 177 | 23,756 (0%) | 0% | 4.1 | 731 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 180 | 23,933 (0%) | 0% | 4.9 | 889 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 218 | 24,113 (0%) | 0% | 5.5 | 1,190 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 1,282 | 24,331 (0%) | 0% | 6.3 | 8,128 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 115 | 25,613 (0%) | 0% | 4.9 | 558 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 97 | 25,819 (0%) | 0% | 3.5 | 340 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 98 | 25,916 (0%) | 0% | 3.9 | 380 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 02 Sep 2020 | 97 | 26,014 (0%) | 0% | 3.9 | 382 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 04 Aug 2020 | 95 | 26,111 (0%) | 0% | 4.1 | 390 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.82 per share. | 02 Jul 2020 | 97 | 26,206 (0%) | 0% | 4.8 | 468 | Common Stock |
Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.11 per share. | 03 Jun 2020 | 94 | 26,303 (0%) | 0% | 5.1 | 480 | Common Stock |